Recent advances in lung cancer: Summary of presentations from the 47th annual neeting of the American society of clinical oncology (ASCO) 2011

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

In the last several years, we have made slow but steady progress in developing new treatment strategies for patients with lung cancer. The use of molecularly targeted therapy has made a significant impact on the outcomes of patients with lung cancer. Further research is ongoing to identify more effective ways to target lung cancer. In the recently concluded 47th annual meeting of the American Society of Clinical Oncology, there were several presentations on novel targeted therapies for lung cancer, in addition to the effective and optimal use of existing cytotoxic and targeted therapies for lung cancer. For this review, we have selected presentations that primarily have an impact on clinical practice, and some presentations regarding emerging therapeutic agents.

Original languageEnglish
Pages (from-to)260-265
Number of pages6
JournalJournal of Thoracic Oncology
Volume7
Issue number1
DOIs
StatePublished - Jan 1 2012

Keywords

  • EGFR-TK mutation
  • EML4-ALK
  • Elderly patients
  • Erlotinib
  • Gefitinib
  • Lung cancer
  • Maintenance chemotherapy
  • MetMAb
  • NSCLC
  • Pemetrexed

Fingerprint Dive into the research topics of 'Recent advances in lung cancer: Summary of presentations from the 47th annual neeting of the American society of clinical oncology (ASCO) 2011'. Together they form a unique fingerprint.

  • Cite this